• Exane BNP Paribas upgraded Novo Nordisk (NYSE:NVO) from “Underperform” to “Neutral” amid ongoing legal challenges.
• A class action lawsuit targets investors of Novo Nordisk securities for specific transactions between May and July 2025.
• The stock price has significantly declined from $69.00 to $53.94 due to lowered forecasts impacting performance.

Novo Nordisk (NYSE:NVO) is a leading player among global pharmaceutical companies, celebrated for its focus on diabetes and hormone therapies. Recently, Exane BNP Paribas upgraded NVO’s stock from “Underperform” to “Neutral,” currently trading at around $49.78.

This upgrade arrives amid persistent legal issues facing the company, with Berger Montague PC investigating potential securities violations. A class action lawsuit targets investors who purchased Novo securities from May 7, 2025, to July 28, 2025, providing them an opportunity for representation in the upcoming proceedings.

Following an announcement in July regarding lowered sales forecasts and profit guidance for the second half of fiscal 2025, Novo Nordisk’s stock price plummeted from $69.00 to $53.94, illustrating a stark decline of over 21% in just one day.

Currently, NVO’s price stands at $49.78, reflecting a minimal decline of 0.18% or $0.09. The stock has fluctuated between $49.38 and $50.31 during the day, with recent trading showing a market cap of roughly $223.3 billion.